Given the upcoming deadline, Lopez McHugh, LLP will discontinue evaluations of Benicar lawsuits after August 19, 2017.
A $300 million settlement was announced on August 1 over the popular blood pressure medication Benicar. The Benicar settlement follows the filing of thousands of lawsuits and several years of litigation against the drug’s makers – Daiichi Sankyo and Forest Laboratories. Benicar lawsuits have alleged that manufacturers did not adequately warn of the association between Benicar and gastrointestinal problems; namely sprue-like enteropathy.
If you or a loved one suffered an injury related to the use of the blood pressure drug Benicar (Olmesartan) before August 1, 2017, please contact the Benicar lawyers at Lopez McHugh, LLP immediately at 877-703-7070 or via our website for a free case evaluation. Time is limited for enrollment in the Benicar settlement and you may be entitled to compensation.
Click here to learn more about the terms of the recently announced settlement and the rapidly approaching deadlines. Eligible claimants with unfiled cases must retain an attorney before August 23, 2017. To be eligible for participation, claimants must have used Benicar for 30 days or more prior to May 1, 2015 and have been diagnosed with an injury such as sprue-like enteropathy, villous atrophy, or celiac-like enteropathy with documented significant weight loss prior to August 1, 2017. The settlement is only open to residents of the United States.
Daiichi-Sankyo continues to maintain the Benicar lawsuits are without merit and has made clear that, although they are offering a settlement, this is not an admission of liability. Company Chairman, Glenn Gormley, has been quoted as saying “Daiichi-Sankyo is committed to the health and safety of all patients taking our medications. We believe a settlement is in the best interest of all, and will allow us to continue our focus on bringing to market innovative medicines that help people live healthy and meaningful lives.”
